BPC-157 + TB-500 Blend 10mg / 10mg

For research use only — not for human or veterinary use.

Analytical Verification (COA)

Each batch of BPC-157 / TB-500 Blend supplied by Grail Formula undergoes independent third-party laboratory verification to confirm compound identity, assay content, purity and microbiological safety.

Analytical testing for this batch was performed by Liquilabs s.r.o. (Czechia) using validated chromatographic and spectrometric techniques.

Batch: GF092025046

Key analytical results include:

• BPC-157 Assay Content: 11.03 mg
• TB-500 (Thymosin Beta-4) Assay Content: 10.84 mg
• Bacterial Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected

Independent heavy metal screening confirmed no detectable levels of arsenic, cadmium, cobalt, lead, nickel, mercury or vanadium.

These analytical procedures ensure traceability, purity verification and laboratory-grade compound consistency.

Product Overview

The BPC-157 / TB-500 blend is a dual-peptide research preparation combining two synthetic peptides frequently studied in experimental laboratory environments investigating cellular signalling and tissue-related biochemical pathways.

The formulation contains both BPC-157 and TB-500 peptides in a single lyophilized preparation designed for controlled laboratory experimentation and comparative peptide interaction research.

This preparation contains a combined 20 mg of high purity lyophilized peptide material supplied in a sealed research vial. The lyophilization process preserves molecular stability and allows researchers to reconstitute the compounds for controlled in vitro experimentation.

Because of the defined peptide sequences and verified analytical profile, peptide combinations such as BPC-157 and TB-500 are frequently referenced in experimental studies exploring peptide-mediated cellular signalling systems.

Compound Overview

BPC-157 is a synthetic peptide derived from a protein fragment originally identified within gastric peptide research models.

TB-500 refers to a synthetic form of the active peptide sequence derived from thymosin beta-4, a naturally occurring protein associated with cellular structural and signalling systems.

Within biochemical research environments, both peptides are commonly investigated for their interaction with cellular signalling networks, cytoskeletal regulation pathways and molecular regulatory mechanisms.

The combination of these peptides within a single preparation allows researchers to explore comparative peptide behaviour and interaction dynamics within controlled laboratory models.

Historical Background and Scientific Context

Research into synthetic peptides expanded significantly during the late twentieth century as advances in peptide synthesis enabled scientists to isolate and replicate biologically active peptide fragments.

During the 1990s and early 2000s, researchers began investigating small peptides derived from larger biological proteins to study their signalling behaviour within controlled laboratory models.

Both BPC-157 and thymosin-derived peptides have since been referenced in experimental biochemical research exploring peptide-mediated cellular regulatory systems.

Modern peptide research often investigates combinations of experimental peptides to study signalling pathway interactions and comparative molecular behaviour.

Mechanistic Focus in Research

Within experimental laboratory environments, the BPC-157 / TB-500 blend is studied in relation to peptide-mediated cellular signalling pathways and molecular regulatory systems.

Research investigations commonly explore the peptides in experimental models examining:

• Peptide-receptor interaction mechanisms
• Cellular signalling pathway dynamics
• Cytoskeletal regulation systems
• Intracellular regulatory network modelling
• Comparative peptide interaction studies
• Molecular signalling cascade analysis
• Peptide-mediated biochemical processes

These experimental models allow scientists to investigate molecular regulatory mechanisms influencing cellular signalling behaviour and biochemical pathway interactions.

Research Applications

In controlled research environments, the BPC-157 / TB-500 blend may be utilised in experimental models designed to explore peptide signalling systems and intracellular regulatory pathways.

Examples of research applications include:

• Peptide signalling pathway investigation
• Comparative peptide interaction research
• Cell signalling analysis
• Molecular regulatory pathway studies
• Intracellular signalling network modelling
• Experimental biochemical peptide research
• Controlled in vitro peptide interaction studies

Grail Formula Quality

Every Grail Formula research compound is produced under strict quality control procedures designed to support reliable laboratory experimentation.

Each batch undergoes independent analytical testing to verify:

• Compound identity
• Assay accuracy
• Purity confirmation
• Microbial safety
• Endotoxin levels
• Heavy metal screening
• Full batch traceability

All testing is performed by independent laboratories to ensure transparent verification and reproducible research material.

Research Use Limitation

• Used solely for in vitro experiments
• Not permitted for clinical trials involving humans
• Not permitted for human or veterinary administration
• Not permitted for investigational human use

• Verified and analysed with Liquilabs s.r.o. Czechia
• Assay content BPC-157 11.03 mg and TB-500 10.84 mg
• No detectable heavy metals or microbial contamination
• Endotoxin level below 0.001 EU per mg
• Batch GF092025046 – Published November 2025
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.